This chapter discusses first-line and second-line therapy for patients with extensive-stage small cell lung cancer (ED SCLC). As first-line therapy, a platinum agent plus etoposide or irinotecan remains the standard of care for the treatment of SCLC. However, despite an initially high response ...
Find out about TECENTRIQ® (atezolizumab) for the treatment of extensive-stage small cell lung cancer (ES-SCLC). See full safety for more information.
Find out about TECENTRIQ® (atezolizumab) for the treatment of extensive-stage small cell lung cancer (ES-SCLC). See full safety for more information.
Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more than two decades without clinical progress, the addition of programmed cell death protein 1 axis blockade to platinum-based chemotherapy has demonstrated sustained overall survival benefit and represents the current...
Treatment options for patients with relapsed extensive-stage small cell lung cancer (ES-SCLC) remain scarce. This study aims to evaluate the efficacy and safety of combining anlotinib and sintilimab plus chemotherapy as a second line or ... X Han,J Guo,L Li,... - 《Signal Transduction &...
Thirty years ago, there was a pervasive atmosphere of pessimism concerning the management of small cell lung cancer (SCLC). Local therapies alone for the t... NH Hanna,LH Einhorn - Springer Berlin Heidelberg 被引量: 9发表: 2004年 Treatment of Extensive Stage Small Cell Lung Cancer Over the...
AstraZeneca’s Imfinzi (durvalumab) has been approved in Japan for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with etoposide plus a choice of platinum chemotherapy (either carboplatin or cisplatin). SCLC is a highly aggressive, fast-growing for...
Small cell lung cancer (SCLC) is a highly malignant and poor-prognosis cancer, with most cases diagnosed at the extensive stage (ES). Amidst a landscape marked by limited progress in treatment modalities for ES-SCLC over the past few decades, the integra
Durvalumab (IMFINZI), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). In the ...
Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. Treatment for extensive-stage small cell lung cancer (ES SCLC) or extrapulmonary small cell carcinoma (EPSC) is typically palliative. We set out to determi... AD Elias,AT...